Front Row Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Front Row Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-200	Closed	-$3.25K	–	809
2024 Q2	$3.25K	Hold	200	–	–	﹤0.01%	799
2024 Q1	$2.82K	Buy	+200	New	+$2.52K	﹤0.01%	806
2023 Q4	–	Sell	-200	Closed	-$2.04K	–	776
2023 Q3	$2.04K	Hold	200	–	–	﹤0.01%	813
2023 Q2	$2K	Hold	200	–	–	﹤0.01%	824
2023 Q1	$2K	Hold	200	–	–	﹤0.01%	840
2022 Q4	$2K	Hold	200	–	–	﹤0.01%	806
2022 Q3	$2K	Hold	200	–	–	﹤0.01%	839
2022 Q2	$2K	Hold	200	–	–	﹤0.01%	847
2022 Q1	$2K	Hold	200	–	–	﹤0.01%	876
2021 Q4	$2K	Hold	200	–	–	﹤0.01%	892
2021 Q3	$2K	Hold	200	–	–	﹤0.01%	882
2021 Q2	$2K	Hold	200	–	–	﹤0.01%	884
2021 Q1	$2K	Hold	200	–	–	﹤0.01%	884
2020 Q4	$2K	Hold	200	–	–	﹤0.01%	844
2020 Q3	$2K	Hold	200	–	–	﹤0.01%	842
2020 Q2	$2K	Hold	200	–	–	﹤0.01%	872
2020 Q1	$2K	Hold	200	–	–	﹤0.01%	848
2019 Q4	$2K	Hold	200	–	–	﹤0.01%	809
2019 Q3	$1K	Hold	200	–	–	﹤0.01%	885
2019 Q2	$2K	Sell	200 -702	-78%	-$8.46K	﹤0.01%	865
2019 Q1	$14K	Buy	902 +401	+80%	+$7.07K	0.01%	389
2018 Q4	$8K	Sell	501 -285	-36%	-$5.84K	0.01%	448
2018 Q3	$16	Sell	786 -3	-0.4%	-$70	0.01%	340
2018 Q2	$18	Buy	789 +251	+47%	+$5.12K	0.01%	347
2018 Q1	$9K	Sell	538 -6	-1%	-$117	0.01%	459
2017 Q4	$10K	Buy	+544	New	+$8.18K	0.01%	437

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

IAM

Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Front Row Advisors's TEVA Position: Q3 2024 in Review

Front Row Advisors sold out of Teva Pharmaceuticals (TEVA) in Q3 2024, closing a stake of 200 shares — an estimated $3.25K sold.

Front Row Advisors first reported a position in TEVA in Q4 2017 and held it in 26 quarters. The position peaked at $14K in Q1 2019. 542 funds tracked by Wall St. Rank hold TEVA as of Q3 2024.

Front Row Advisors reported no remaining Teva Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Front Row Advisors sold 200 Teva Pharmaceuticals shares in Q3 2024, an estimated $3.25K.
Front Row Advisors first reported a position in Teva Pharmaceuticals in Q4 2017 and held it in 26 quarters.
Front Row Advisors's Teva Pharmaceuticals position peaked at $14K in Q1 2019.
542 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2024.

Based on Front Row Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.